^
Association details:
| Biomarker: | EML4-ALK fusion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | ganetespib (ADX-1612) (HSP90 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Targeted Inhibition of the Molecular Chaperone Hsp90 Overcomes ALK Inhibitor Resistance in Non–Small Cell Lung Cancer
Excerpt:
The H2228 NSCLC cell line expresses an E6a/b;A20 EML4–ALK fusion protein and, as shown in Fig. 1A, was comparatively more sensitive to the cytotoxic effects of ganetespib than crizotinib (IC50 values of 13 vs. 202 nmol/L, respectively)... Ganetespib (Supplementary Fig. S1) treatment resulted in a robust and dose-dependent destabilization of EML4–ALK, as well as EGFR and MET, all established Hsp90 clients...
DOI:
10.1158/2159-8290.CD-12-0440
